艾昆纬IQVIA：2025年释放生物类似药潜力：骨质疏松症患者案例研究报告（英文版）

Physician experiences with biosimilars have increased substantially in Europe over the past few years, driven by an increased policy focus, greater comfort, and regulatory guidance. These biosimilars have also provided savings for the overall health system and have played a crucial role in enhancing sustainability of this system. Several new biosimilars are expected to launch over the next five years and ensuring their optimal use will be important.Understanding physician perspectives on bios